Åsa Dahle-Smith

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

Susan Dutton, David Ferry, Jane Blazeby et al. · The Lancet Oncology · 2014 · 329 citations · Full text

Esophageal Cancer, Gastrointestinal Oncology, Medicine +6

Gefitinib and <i>EGFR</i> Gene Copy Number Aberrations in Esophageal Cancer

Russell Petty, Åsa Dahle-Smith, David A. Stevenson et al. · Journal of Clinical Oncology · 2017 · 137 citations · Full text

Tumor Biology, Radiation Oncology, Esophageal Cancer +15

Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas

Simona Corso, Filippo Pietrantonio, Maria Apicella et al. · Clinical Cancer Research · 2021 · 21 citations · Full text

Phase III Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of Gefitinib versus Placebo in Esophageal Cancer Progressing after Chemotherapy, COG (Cancer Oesophagus Gefitinib)

D. Ferry, S.J. Dutton, Wasat Mansoor et al. · Annals of Oncology · 2012 · 16 citations

Surgical Oncology, Oncology, Esophageal Cancer +6

Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG).

Russell Petty, Åsa Dahle-Smith, Zosia Miedzybrodzka et al. · Journal of Clinical Oncology · 2014 · 15 citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +15